DKK1 and ovarian carcinoma: In ovarian cancer, the deadliest of the gynecological tumors, DKK1 overexpression provides a tumor-friendly microenvironment to inhibit the anti-tumor immune cell populations, which may have a leading role in combination immunoregulatory therapy (Bray et al., 2018; Betella et al., 2020).